adagrasib
mirati
['nsclc', 'sclc', 'adagrasib']
adagrasib shows impressive data in metastatic nsclc pts w/krasg12c mutation. produced responses in 43% of previously treated patients with #nsclc containing a krasg12c mutation, with median os of 12.6 months. #asco22
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.